BRPI0509936A - peptìdios terapêuticos - Google Patents

peptìdios terapêuticos

Info

Publication number
BRPI0509936A
BRPI0509936A BRPI0509936-6A BRPI0509936A BRPI0509936A BR PI0509936 A BRPI0509936 A BR PI0509936A BR PI0509936 A BRPI0509936 A BR PI0509936A BR PI0509936 A BRPI0509936 A BR PI0509936A
Authority
BR
Brazil
Prior art keywords
therapeutic peptides
ligand
product
sulfonation
hydroxylation
Prior art date
Application number
BRPI0509936-6A
Other languages
English (en)
Inventor
Mumtaz Virji
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408390A external-priority patent/GB0408390D0/en
Priority claimed from GB0419594A external-priority patent/GB0419594D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of BRPI0509936A publication Critical patent/BRPI0509936A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEPTìDIOS TERAPêUTICOS. A presente invenção refere-se a um ligante isolado de proteína de membrana externa de Moraxella catarrhalis, que se liga a receptores de CEACAM, o dito ligante compreendendo um domínio de ligação de receptor compreendendo uma seqüência de aminoácidos selecionada do grupo descrito, ou um fragmento, homólogo, equivalente funcional, derivado, degenerado ou produto de hidroxilação, sulfonação ou glicosilação ou outro produto de processamento secundário da mesma. A invenção também proporciona medicamentos e vacinas compreendendo o dito ligante, e o seu uso no tratamento ou profilaxia da infecção. Também se proporciona um método de triagem para a identificação de novos compostos terapêuticos.
BRPI0509936-6A 2004-04-15 2005-04-15 peptìdios terapêuticos BRPI0509936A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0408390A GB0408390D0 (en) 2004-04-15 2004-04-15 Therapeutic peptides
GB0419594A GB0419594D0 (en) 2004-09-03 2004-09-03 Therapeutic peptides
PCT/GB2005/001465 WO2005099337A2 (en) 2004-04-15 2005-04-15 Therapeutic peptides

Publications (1)

Publication Number Publication Date
BRPI0509936A true BRPI0509936A (pt) 2007-09-25

Family

ID=35033424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509936-6A BRPI0509936A (pt) 2004-04-15 2005-04-15 peptìdios terapêuticos

Country Status (11)

Country Link
EP (2) EP1735446A2 (pt)
JP (2) JP4960219B2 (pt)
KR (1) KR20070001274A (pt)
AU (1) AU2005232437B2 (pt)
BR (1) BRPI0509936A (pt)
CA (1) CA2563332A1 (pt)
IL (1) IL178517A0 (pt)
MX (1) MXPA06011501A (pt)
NO (1) NO20065201L (pt)
NZ (1) NZ551204A (pt)
WO (1) WO2005099337A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
EP2042187A1 (en) * 2007-09-27 2009-04-01 Charité-Universitätsmedizin Berlin (Charité) Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis
EP3087099A4 (en) * 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2022108982A1 (en) * 2020-11-17 2022-05-27 Yale University Targeting host-bacteria interactions for the treatment of microbiota-mediated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746442B2 (en) * 1996-12-20 2002-05-02 Board Of Regents, The University Of Texas System UspA1 and UspA2 antigens of Moraxella catarrhalis
GB0222764D0 (en) * 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide

Also Published As

Publication number Publication date
WO2005099337A2 (en) 2005-10-27
MXPA06011501A (es) 2007-01-26
KR20070001274A (ko) 2007-01-03
WO2005099337A3 (en) 2006-08-10
AU2005232437B2 (en) 2011-10-06
EP1735446A2 (en) 2006-12-27
JP2012097099A (ja) 2012-05-24
CA2563332A1 (en) 2005-10-27
EP2468863A1 (en) 2012-06-27
AU2005232437A1 (en) 2005-10-27
NZ551204A (en) 2010-03-26
JP4960219B2 (ja) 2012-06-27
NO20065201L (no) 2006-11-13
IL178517A0 (en) 2007-02-11
JP2007532618A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
Ratanabanangkoon et al. A simple and novel strategy for the production of a pan-specific antiserum against elapid snakes of Asia
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
El-Bitar et al. Smp76, a scorpine-like peptide isolated from the venom of the scorpion Scorpio maurus palmatus, with a potent antiviral activity against hepatitis C virus and dengue virus
Zhang et al. Tongue sole (Cynoglossus semilaevis) prothymosin alpha: cytokine-like activities associated with the intact protein and the C-terminal region that lead to antiviral immunity via Myd88-dependent and-independent pathways respectively
NO20083793L (no) Antistoffer mot amyloid-beta peptid
RU2012149227A (ru) Биологические материалы, относящиеся к her3
JP2003521477A (ja) プリオン蛋白質ペプチドおよびその使用
AU2013268364A1 (en) Therapeutic agent or prophylactic agent for dementia
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
Kirk et al. Distribution of the SynDIG4/proline‐rich transmembrane protein 1 in rat brain
AR122213A1 (es) Anticuerpos anti-cd200r1 y métodos de uso de estos
AR117327A1 (es) Anticuerpos anti-cd96 y métodos de uso de estos
BR112020022655A2 (pt) epítopo de antígeno de superfície de células t reguladoras e anticorpo que se liga especificamente ao mesmo
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR0315031A (pt) Peptìdios terapêuticos
WO2005099337A3 (en) Therapeutic peptides
Huai et al. Interaction of transient receptor potential vanilloid 4 with annexin A2 and tubulin beta 5
Ronzitti et al. Yessotoxin induces the accumulation of altered E-cadherin dimers that are not part of adhesive structures in intact cells
BR112018069332A2 (pt) composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer
Lv et al. Expression profile, localization of an 8-kDa calcium-binding protein from Schistosoma japonicum (SjCa8), and vaccine potential of recombinant SjCa8 (rSjCa8) against infections in mice
Torrealba et al. Selenium-binding protein-1 in smooth muscle cells is downregulated in a rhesus monkey model of chronic allograft nephropathy
WO2020263650A1 (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.